Market Overview:
The global gadolinium contrast media market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of chronic diseases, rising demand for minimally invasive surgeries, and technological advancements in medical imaging procedures. Based on type, the global gadolinium contrast media market is segmented into gadobutrol, gadopentetate dimeglumine, gadoterate meglumine, gadobenate dimeglumine, and others. Gadopentetate dimeglumine held the largest share of the global market in 2017 owing to its high usage rates in magnetic resonance imaging (MRI) procedures. Gadoteridol is expected to be the fastest-growing type segment during the forecast period due to its growing use as a diagnostic agent for neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis (MS). Based on application, hospitals accounted for majority ofthe global demand for gadolinium contrast mediain 2017 owingto their large patient baseand increasing numberof minimally invasive surgeries being performed worldwide.
Product Definition:
Gadolinium contrast media is a substance used to improve the visibility of internal body structures in medical imaging. Gadolinium is a metal with a high atomic number that emits X-rays very well, allowing it to be used as a contrast agent to highlight certain areas in an image. Contrast agents are often used in medical imaging procedures such as CT scans and MRIs to improve the clarity of images and help doctors diagnose conditions. Gadolinium contrast media is considered safe and effective for use in most patients.
Gadobutrol:
Gadobutrol is a gadolinium-based contrast agent used in MRI. It has high molecular weight and low water solubility. The drug was first registered by Bayer Healthcare AG in Germany and later on approved for medical use by the U.
Gadopentetate Dimeglumine:
Gadopentetate Dimeglumine is a gadolinium-based contrast agent used in MRI. It has low molecular weight and high water solubility. Gadopentetate Dimeglumine is an analog of pent tetraethylene glycol, which has been modified by the addition of dimethylarginine (DMA) group.
Application Insights:
The clinics segment dominated the global market in 2017. This can be attributed to factors such as increasing awareness about availability of contrast media and rising incidences of cardiovascular diseases, cerebrovascular disorders, and peripheral vascular diseases. The hospitals segment is expected to witness lucrative growth over the forecast period due to growing investments by governments in the development of healthcare infrastructure along with technological advancements that have led to an increase in efficiency.
Hospitals are considered better equipped than clinics for providing effective care owing to advanced diagnostic facilities along with a larger number of staff members skilled enough for carrying out complex procedures using radiological imaging techniques.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of major manufacturers and well-established healthcare infrastructure. In addition, increasing incidence of brain tumor is expected to drive regional growth over the forecast period. Asia Pacific is expected to grow at a lucrative rate over the forecast period due to rising awareness about diagnostic imaging and growing medical tourism industry in this region. Moreover, increasing government initiatives are projected to fuel revenue growth in this region during the forecast period. For instance, Gadolinium contrast media was approved for reimbursement under India's public health insurance scheme known as Rashtriya Arogya Nidhi (RAN) by National Health Mission from 2014-15 fiscal year which covered around 60 million population out of which 50% were below poverty line families living in rural areas & 40% were urban poor living in slums & unauthorized colonies).
Growth Factors:
- Increasing incidence of cancer and other diseases requiring diagnosis and treatment with contrast media
- Growing demand for minimally invasive diagnostic procedures
- Advances in medical imaging technology that increase the use of contrast media
- Rising healthcare expenditure by governments and private insurers worldwide
- Proliferation of clinical research studies on the benefits of gadolinium contrast media
Scope Of The Report
Report Attributes
Report Details
Report Title
Gadolinium Contrast Media Market Research Report
By Type
Gadobutrol, Gadopentetate Dimeglumine, Gadoterate Meglumine, Gadobenate Dimeglumine, Gadoteridol, Others
By Application
Hospitals, Clinics
By Companies
Bayer, Takeda, Fuji Pharma, Towaseiyaku, Hikari Pharmaceutical, BeiLu Pharma, Guerbet, GE, Sanochemia, T2Pharma, Bayer, Hengrui Medicine, Bracco
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Gadolinium Contrast Media Market Report Segments:
The global Gadolinium Contrast Media market is segmented on the basis of:
Types
Gadobutrol, Gadopentetate Dimeglumine, Gadoterate Meglumine, Gadobenate Dimeglumine, Gadoteridol, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Takeda
- Fuji Pharma
- Towaseiyaku
- Hikari Pharmaceutical
- BeiLu Pharma
- Guerbet
- GE
- Sanochemia
- T2Pharma
- Bayer
- Hengrui Medicine
- Bracco
Highlights of The Gadolinium Contrast Media Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Gadobutrol
- Gadopentetate Dimeglumine
- Gadoterate Meglumine
- Gadobenate Dimeglumine
- Gadoteridol
- Others
- By Application:
- Hospitals
- Clinics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gadolinium Contrast Media Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gadolinium contrast media is a type of imaging agent that helps doctors see structures inside the body more clearly. It is often used to help diagnose medical conditions, such as cancer.
Some of the major companies in the gadolinium contrast media market are Bayer, Takeda, Fuji Pharma, Towaseiyaku, Hikari Pharmaceutical, BeiLu Pharma, Guerbet, GE, Sanochemia, T2Pharma, Bayer, Hengrui Medicine, Bracco.
The gadolinium contrast media market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gadolinium Contrast Media Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gadolinium Contrast Media Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gadolinium Contrast Media Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gadolinium Contrast Media Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gadolinium Contrast Media Market Size & Forecast, 2018-2028
4.5.1 Gadolinium Contrast Media Market Size and Y-o-Y Growth
4.5.2 Gadolinium Contrast Media Market Absolute $ Opportunity
Chapter 5 Global Gadolinium Contrast Media Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gadolinium Contrast Media Market Size Forecast by Type
5.2.1 Gadobutrol
5.2.2 Gadopentetate Dimeglumine
5.2.3 Gadoterate Meglumine
5.2.4 Gadobenate Dimeglumine
5.2.5 Gadoteridol
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gadolinium Contrast Media Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gadolinium Contrast Media Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gadolinium Contrast Media Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gadolinium Contrast Media Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gadolinium Contrast Media Analysis and Forecast
9.1 Introduction
9.2 North America Gadolinium Contrast Media Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gadolinium Contrast Media Market Size Forecast by Type
9.6.1 Gadobutrol
9.6.2 Gadopentetate Dimeglumine
9.6.3 Gadoterate Meglumine
9.6.4 Gadobenate Dimeglumine
9.6.5 Gadoteridol
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gadolinium Contrast Media Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gadolinium Contrast Media Analysis and Forecast
10.1 Introduction
10.2 Europe Gadolinium Contrast Media Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gadolinium Contrast Media Market Size Forecast by Type
10.6.1 Gadobutrol
10.6.2 Gadopentetate Dimeglumine
10.6.3 Gadoterate Meglumine
10.6.4 Gadobenate Dimeglumine
10.6.5 Gadoteridol
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gadolinium Contrast Media Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gadolinium Contrast Media Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gadolinium Contrast Media Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gadolinium Contrast Media Market Size Forecast by Type
11.6.1 Gadobutrol
11.6.2 Gadopentetate Dimeglumine
11.6.3 Gadoterate Meglumine
11.6.4 Gadobenate Dimeglumine
11.6.5 Gadoteridol
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gadolinium Contrast Media Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gadolinium Contrast Media Analysis and Forecast
12.1 Introduction
12.2 Latin America Gadolinium Contrast Media Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gadolinium Contrast Media Market Size Forecast by Type
12.6.1 Gadobutrol
12.6.2 Gadopentetate Dimeglumine
12.6.3 Gadoterate Meglumine
12.6.4 Gadobenate Dimeglumine
12.6.5 Gadoteridol
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gadolinium Contrast Media Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gadolinium Contrast Media Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gadolinium Contrast Media Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gadolinium Contrast Media Market Size Forecast by Type
13.6.1 Gadobutrol
13.6.2 Gadopentetate Dimeglumine
13.6.3 Gadoterate Meglumine
13.6.4 Gadobenate Dimeglumine
13.6.5 Gadoteridol
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gadolinium Contrast Media Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gadolinium Contrast Media Market: Competitive Dashboard
14.2 Global Gadolinium Contrast Media Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Takeda
14.3.3 Fuji Pharma
14.3.4 Towaseiyaku
14.3.5 Hikari Pharmaceutical
14.3.6 BeiLu Pharma
14.3.7 Guerbet
14.3.8 GE
14.3.9 Sanochemia
14.3.10 T2Pharma
14.3.11 Bayer
14.3.12 Hengrui Medicine
14.3.13 Bracco
